Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Odontogenic Cysts 2Lung Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Nose Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Nivolumab 6atezolizumab 5Cisplatin 5Ipilimumab 4Carboplatin 4Etoposide 3pembrolizumab 2gallium Ga 68 dotatate 2dostarlimab 2Temozolomide 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Magnetic Resonance Imaging 2Irinotecan 2Immunoglobulin G 2IFL protocol 2Disulfides 2zimberelimab 1tivozanib 1repotrectinib 1niraparib 1lutetium Lu 177 dotatate 1lenvatinib 1iadademstat 1durvalumab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Radionuclide Imaging × 1 year × Clear all
NCT04069299 2026-03-31

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

H. Lee Moffitt Cancer Center and Research Institute

Completed
30 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡